Scalper1 News
UBS downgraded Regeneron (REGN) and Amgen (AMGN) and adjusted the price targets on several other biotech stocks Thursday on the grounds that the sector may be in for a slow patch. “Although we still think that biotech will continue to outperform the broader markets and the Health Care SPDR (XLV), we are getting more selective with our price targets and ratings considering fewer near-term catalysts with the power to drive material upward revisions Scalper1 News
Scalper1 News